Lipid mediated formation of hemozoin

脂质介导的疟原虫色素的形成

基本信息

  • 批准号:
    7687735
  • 负责人:
  • 金额:
    $ 9.92万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-08-15 至 2013-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Formation of the malarial pigment hemozoin, a microcrystalline dimer of heme, is one of the most important processes disrupted by drugs in the protozoan malaria parasite Plasmodium and is also a potential drug target in the parasitic helminth worm Schistosoma. However, the mechanism of its formation and inhibition is currently poorly understood. Since recent evidence suggests that hemozoin formation occurs within lipid (i.e. fat) droplets, the project aims to investigate the characteristics of artificial lipid droplets and the rates of beta-hematin (synthetic hemozoin) formation in these artificial lipid droplets in order to better understand the process and to develop improved methods for finding new beta-hematin inhibiting scaffolds as a first step to the discovery of antimalarial and antischistosomal drugs. To achieve this, the following specific aims are proposed: SPECIFIC AIM 1. Investigate the interaction of heme with neutral lipids. SPECIFIC AIM 2. Study the rate of beta-hematin formation at lipid/water interfaces and in lipid droplets dispersed in water. SPECIFIC AIM 3. Translate our understanding of lipid droplet mediated beta-hematin formation into a high throughput screen for potential new drug scaffolds. In order to achieve these goals, the research will be conducted as a collaborative project between Timothy J. Egan at the University of Cape Town, South Africa and David W. Wright at Vanderbilt University, Nashville, TN. Studies on the behavior of neutral lipids at water surfaces and of the interaction of heme with lipids as well as on the rates of beta-hematin formation will be conducted in Cape Town. Development of the high throughput screen will be conducted at Vanderbilt University and will then be used to screen the extensive Vanderbilt University compound library at the University's high throughput screening facility. This is expected to lead to the identification of new beta-hematin inhibiting scaffolds. The collaboration between the two groups will be strongly synergistic. The considerable expertise on lipid mediated beta-hematin formation and especially studies on the rates of this process will be transferred from the University of Cape Town to Vanderbilt University. Conversely, expertise on high throughput screening methods will be transferred from Vanderbilt University to the University of Cape Town. PUBLIC HEALTH RELEVANCE Malaria and schistosomiasis are the two most important human parasitic diseases affecting hundreds of millions of people around the world. Both parasites feed on blood with the consequent need for them to detoxify heme. Formation of hemozoin, a microcrystalline dimer of heme, is one of the most important processes disrupted by drugs in the malaria parasite Plasmodium and is also a potential target in the helminth parasite Schistosoma. However, the mechanism of its formation and inhibition is currently poorly understood. We propose to undertake research to better understand the process and to use this to knowledge to develop screening methods for discovering new compounds that disrupt the process as a first step to discovery of new antimalarial and antischistosomal drugs.
描述(由申请方提供):疟原虫色素疟原虫色素(一种血红素的微晶二聚体)的形成是原生动物疟疾寄生虫疟原虫中被药物破坏的最重要过程之一,也是寄生蠕虫血吸虫中的潜在药物靶标。然而,其形成和抑制的机制目前知之甚少。由于最近的证据表明,疟原虫色素的形成发生在脂质中,(即脂肪)液滴,该项目旨在研究人工脂滴的特性和β-血红素的比率。为了更好地理解这一过程,并开发出改进的方法来寻找新的β-血红素抑制支架作为发现抗疟疾和抗疟原虫药物的第一步。为此,提出了以下具体目标:具体目标1。研究血红素与中性脂质的相互作用。具体目标2.研究脂/水界面和分散在水中的脂滴中β-高铁血红素的形成速率。具体目标3.将我们对脂滴介导的β-高铁血红素形成的理解转化为潜在新药支架的高通量筛选。为了实现这些目标,这项研究将作为南非开普敦大学的蒂莫西J.埃根和大卫W.赖特在田纳西州纳什维尔的范德比尔特大学。将在开普敦进行关于中性脂质在水面上的行为、血红素与脂质的相互作用以及β-血红素形成速率的研究。高通量筛选的开发将在范德比尔特大学进行,然后将用于在该大学的高通量筛选设施中筛选广泛的范德比尔特大学化合物库。这有望导致新的β-血红素抑制支架的鉴定。这两个小组之间的合作将具有很强的协同作用。关于脂质介导的β-血红素形成的大量专业知识,特别是关于该过程速率的研究,将从开普敦大学转移到范德比尔特大学。相反,高通量筛选方法的专业知识将从范德比尔特大学转移到开普敦大学。疟疾和血吸虫病是影响全世界数亿人的两种最重要的人类寄生虫病。这两种寄生虫都以血液为食,因此需要它们对血红素进行解毒。疟原虫色素(血红素的微晶二聚体)的形成是疟疾寄生虫疟原虫中被药物破坏的最重要的过程之一,也是蠕虫寄生虫血吸虫中的潜在靶点。然而,其形成和抑制的机制目前知之甚少。我们建议进行研究以更好地了解这一过程,并利用这一知识来开发筛选方法,以发现破坏该过程的新化合物,作为发现新的抗疟疾和抗血吸虫药物的第一步。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Timothy John Egan其他文献

Timothy John Egan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Timothy John Egan', 18)}}的其他基金

New tools for antimalarial target identification
抗疟靶点识别的新工具
  • 批准号:
    9898297
  • 财政年份:
    2019
  • 资助金额:
    $ 9.92万
  • 项目类别:
Plasmodium heme detoxification probes
疟原虫血红素解毒探针
  • 批准号:
    8661896
  • 财政年份:
    2014
  • 资助金额:
    $ 9.92万
  • 项目类别:
Plasmodium heme detoxification probes
疟原虫血红素解毒探针
  • 批准号:
    9217546
  • 财政年份:
    2014
  • 资助金额:
    $ 9.92万
  • 项目类别:
Plasmodium heme detoxification probes
疟原虫血红素解毒探针
  • 批准号:
    8812778
  • 财政年份:
    2014
  • 资助金额:
    $ 9.92万
  • 项目类别:
Lipid mediated formation of hemozoin
脂质介导的疟原虫色素的形成
  • 批准号:
    7906648
  • 财政年份:
    2009
  • 资助金额:
    $ 9.92万
  • 项目类别:
Lipid mediated formation of hemozoin
脂质介导的疟原虫色素的形成
  • 批准号:
    8122196
  • 财政年份:
    2009
  • 资助金额:
    $ 9.92万
  • 项目类别:
Lipid mediated formation of hemozoin
脂质介导的疟原虫色素的形成
  • 批准号:
    8305400
  • 财政年份:
    2009
  • 资助金额:
    $ 9.92万
  • 项目类别:

相似海外基金

Developing inhibitors of Plasmodium Acetyl CoA Synthetase as new multistage antimalarials
开发疟原虫乙酰辅酶A合成酶抑制剂作为新型多级抗疟药
  • 批准号:
    MR/X030202/1
  • 财政年份:
    2023
  • 资助金额:
    $ 9.92万
  • 项目类别:
    Research Grant
Novel Dual-Stage Antimalarials: Machine learning prediction, validation and evolution
新型双阶段抗疟药:机器学习预测、验证和进化
  • 批准号:
    10742205
  • 财政年份:
    2023
  • 资助金额:
    $ 9.92万
  • 项目类别:
Natural Product Inspired Novel Antimalarials with Radical Cure Potential
受天然产物启发的具有根治潜力的新型抗疟药
  • 批准号:
    10635649
  • 财政年份:
    2023
  • 资助金额:
    $ 9.92万
  • 项目类别:
Novel Synergistic Antimalarials with Resistance Reversal Function
具有耐药逆转功能的新型协同抗疟药
  • 批准号:
    10534667
  • 财政年份:
    2022
  • 资助金额:
    $ 9.92万
  • 项目类别:
Plasmodium Protein Kinase Focused Antimalarials Discovery
疟原虫蛋白激酶聚焦抗疟药的发现
  • 批准号:
    10533634
  • 财政年份:
    2022
  • 资助金额:
    $ 9.92万
  • 项目类别:
DMPK Optimisation of B-hydroxyethylamine Antimalarials
B-羟乙胺抗疟药的 DMPK 优化
  • 批准号:
    2749037
  • 财政年份:
    2022
  • 资助金额:
    $ 9.92万
  • 项目类别:
    Studentship
Development of new lead antimalarials targeting parasite coenzyme A biosynthesis and utilisation.
开发针对寄生虫辅酶 A 生物合成和利用的新型先导抗疟药。
  • 批准号:
    468862
  • 财政年份:
    2022
  • 资助金额:
    $ 9.92万
  • 项目类别:
    Operating Grants
Repurposing antimalarials for the treatment of NTM infections
重新利用抗疟药治疗 NTM 感染
  • 批准号:
    10646331
  • 财政年份:
    2022
  • 资助金额:
    $ 9.92万
  • 项目类别:
Novel Synergistic Antimalarials with Resistance Reversal Function
具有耐药逆转功能的新型协同抗疟药
  • 批准号:
    10368441
  • 财政年份:
    2022
  • 资助金额:
    $ 9.92万
  • 项目类别:
Plasmodium Protein Kinase Focused Antimalarials Discovery
疟原虫蛋白激酶聚焦抗疟药的发现
  • 批准号:
    10663334
  • 财政年份:
    2022
  • 资助金额:
    $ 9.92万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了